Physician profile
James C Mcalpine
NPI 1851343636
$1,394.86
in general payments reported to CMS, 2019-2025
24 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $315 · 2021: $442 · 2022: $75.20 · 2023: $71.93 · 2024: $39.70 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $292.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $111.68 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $108.70 | 2019-2025 | Freestyle Libre 3, Octrode |
| Novo Nordisk INC | $89.84 | 2020-2021 | |
| Abbvie INC. | $79.65 | 2021-2022 | |
| Astellas Pharma US INC | $77.96 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.83 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $63.57 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $54.36 | 2020-2021 | |
| Amgen INC. | $53.00 | 2020-2021 | |
| Pfizer INC. | $47.90 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $45.82 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.24 | 2020 | |
| Amarin Pharma, INC. | $43.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $34.38 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.40 | 2019-2021 | |
| Lilly USA, LLC | $23.45 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $19.27 | 2019 | |
| Seqirus USA INC | $19.07 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $18.93 | 2023 | Prehevbrio |
| Acadia Pharmaceuticals INC | $17.96 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.41 | 2021 | |
| Eisai INC. | $17.00 | 2020 | |
| Allergan, INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcalpine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.